NAVCO Pharmaceuticals Inc. (TSXV:NAV)
Canada · Delayed Price · Currency is CAD 0.0050
0.00 (0.00%)
Aug 18, 2026, 2:19 PM EST
NAVCO Pharmaceuticals Balance Sheet
Financials in millions CAD. Fiscal year is October - September.
Millions CAD. Fiscal year is Oct - Sep.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Equivalents | 0 | 0 | 0.01 | 0.23 | 0 | 0 |
Cash & Short-Term Investments | 0 | 0 | 0.01 | 0.23 | 0 | 0 |
Cash Growth | -87.91% | -59.39% | -96.87% | 15187.95% | -62.29% | - |
Other Receivables | - | - | 0.07 | 0.05 | 0.06 | 0.03 |
Receivables | - | - | 0.07 | 0.05 | 0.06 | 0.03 |
Inventory | - | - | - | 0 | 0 | 0.01 |
Prepaid Expenses | - | - | - | 0.43 | - | - |
Total Current Assets | 0 | 0 | 0.07 | 0.71 | 0.06 | 0.04 |
Property, Plant & Equipment | - | - | 0 | 0.18 | 0.22 | 0.25 |
Other Intangible Assets | - | - | - | 0.04 | 0.05 | 0.05 |
Total Assets | 0 | 0 | 0.08 | 0.93 | 0.32 | 0.35 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Accounts Payable | 0.19 | 0.19 | 0.17 | 0.11 | 0.17 | 0.08 |
Accrued Expenses | 0.04 | 0.04 | 0.03 | 0.13 | 0.04 | 0.01 |
Short-Term Debt | 0.11 | 0.09 | 0.09 | 0.01 | 0.78 | 0.17 |
Current Portion of Leases | - | - | 0.01 | 0.01 | 0.01 | 0.01 |
Other Current Liabilities | 0.63 | 0.63 | 0.63 | 0.49 | - | 0.29 |
Total Current Liabilities | 0.96 | 0.94 | 0.93 | 0.75 | 1.01 | 0.56 |
Long-Term Leases | - | - | - | 0.09 | 0.1 | 0.12 |
Total Liabilities | 0.96 | 0.94 | 0.93 | 0.84 | 1.11 | 0.67 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Common Stock | 4.02 | 4.02 | 4.02 | 3.35 | 0.88 | 0.88 |
Retained Earnings | -5.64 | -5.61 | -5.53 | -3.81 | -1.66 | -1.2 |
Comprehensive Income & Other | 0.66 | 0.66 | 0.66 | 0.55 | - | - |
Shareholders' Equity | -0.96 | -0.94 | -0.86 | 0.09 | -0.79 | -0.32 |
Total Liabilities & Equity | 0 | 0 | 0.08 | 0.93 | 0.32 | 0.35 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Total Debt | 0.11 | 0.09 | 0.1 | 0.11 | 0.9 | 0.29 |
Net Cash (Debt) | -0.1 | -0.08 | -0.09 | 0.12 | -0.9 | -0.29 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.00 | -0.00 | -0.00 | 0.00 | -0.04 | -0.02 |
Filing Date Shares Outstanding | 57.07 | 57.07 | 57.07 | 40.35 | 14.5 | 14.48 |
Total Common Shares Outstanding | 57.07 | 57.07 | 57.07 | 40.35 | 14.5 | 14.48 |
Working Capital | -0.96 | -0.94 | -0.86 | -0.04 | -0.95 | -0.52 |
Book Value Per Share | -0.02 | -0.02 | -0.02 | 0.00 | -0.05 | -0.02 |
Tangible Book Value | -0.96 | -0.94 | -0.86 | 0.05 | -0.83 | -0.38 |
Tangible Book Value Per Share | -0.02 | -0.02 | -0.02 | 0.00 | -0.06 | -0.03 |
Machinery | - | 0.03 | 0.03 | 0.1 | 0.1 | 0.1 |
Leasehold Improvements | - | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 |